Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program

Stock Information for Awakn Life Sciences

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Awakn Life Sciences

Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites
Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing
Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension
Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio
Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.